Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Other Non-Current Assets (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Other Non-Current Assets for 8 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets rose 30.5% to $2.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.0 million, a 30.5% increase, with the full-year FY2024 number at $1.4 million, down 25.03% from a year prior.
  • Other Non-Current Assets was $2.0 million for Q3 2025 at Whitehawk Therapeutics, down from $2.1 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $2.3 million in Q1 2022 to a low of $20000.0 in Q1 2021.
  • A 5-year average of $1.7 million and a median of $2.0 million in 2023 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 11585.0% in 2022, then dropped 25.03% in 2024.
  • Whitehawk Therapeutics' Other Non-Current Assets stood at $2.2 million in 2021, then decreased by 1.58% to $2.2 million in 2022, then decreased by 14.33% to $1.9 million in 2023, then decreased by 25.03% to $1.4 million in 2024, then surged by 41.32% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Other Non-Current Assets are $2.0 million (Q3 2025), $2.1 million (Q2 2025), and $1.4 million (Q1 2025).